Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy Patented technology allows for manufacturing hundreds of therapeutic doses of Killer T cells (Cytotoxic CD8+ T Lymphocytes) from a single donor Tevogen’s investigational T cell therapy, TVGN-489, is designed to detect targetsContinue reading “Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy”
Press Release Archives
Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council
Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council January 5, 2022 METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company, announces the appointment of Sten H. Vermund, M.D., Ph.D., Dean andContinue reading “Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council”